Innovative and Applied Emerging Technologies in Biospecimen Science (R33) | Apply Online

Opportunity Summary:

The Innovative and Applied Emerging Technologies in Biospecimen Science (R33) funding opportunity (RFA-CA-09-005) is a National Cancer Institute (NCI) grant announcement under the NIH’s broader Innovative Molecular Analysis Technologies (IMAT) Program. It is designed to support exceptionally innovative, high-risk, original, and sometimes unconventional early-stage technology development projects that can significantly advance biospecimen science in ways that matter for cancer research. The central idea is to push forward new technology concepts that are not yet mature but have clear potential to transform how biospecimens are collected, assessed, preserved, and ultimately used for high-quality molecular analyses.

A major emphasis of the announcement is improving the quality and utility of biospecimens while keeping invasiveness low and avoiding harm or added risk to donors and patients. In practical terms, the NCI is looking for technologies that either (1) enable better interrogation of biospecimens (for example, by allowing more informative molecular measurements from limited or fragile samples) or (2) maximize biospecimen quality (for example, by preventing degradation or minimizing artifacts introduced during collection, handling, storage, or transport). The FOA also explicitly encourages the development of tools, devices, instrumentation, and related methods that can evaluate sample quality, preserve or protect sample integrity, and establish clear verification criteria for quality assessment and quality control (QA/QC), including under varied and potentially challenging real-world conditions.

The projects that fit best are those that can credibly claim they may produce a major impact in biospecimen science, meaning they go beyond incremental improvements. The intent is to back work at the “inception and early stage development” phase, where the science may be exploratory and the technical risk may be high, but the payoff could be substantial if successful. Because biospecimen quality is a known bottleneck for many downstream molecular applications (such as genomics, transcriptomics, proteomics, and other biomarker-driven approaches), the technologies supported by this FOA are expected to strengthen the reliability, interpretability, and clinical relevance of cancer research findings that depend on biospecimen-derived data.

Administratively, this opportunity is a discretionary NIH grant using the R33 mechanism. It was posted on December 15, 2008, with an original and current closing date of September 30, 2009, and an archive date of October 31, 2009. The estimated total funding amount listed is $1,000,000, and the FOA is associated with multiple CFDA program areas spanning cancer research, including cancer cause and prevention (93.393), detection and diagnosis (93.394), treatment (93.395), and biology (93.396). There is no cost sharing or matching requirement indicated.

Eligibility is broad and includes many organization types: public and private institutions of higher education, small businesses, for-profit organizations (other than small businesses), nonprofit organizations (including those with 501(c)(3) status and certain nonprofits without 501(c)(3) status), and state governments. The eligibility language also notes additional categories, including eligible federal agencies, U.S. territories or possessions, and non-U.S. entities (foreign organizations), indicating the program’s openness to a wide range of capable applicants who can deliver impactful technology innovation in biospecimen science.

Finally, this R33 FOA sits alongside other IMAT funding announcements with similar scientific scope but different funding mechanisms. NIH provided a separate cross-comparison notice (NOT-CA-09-007) to help applicants choose the best-fit mechanism among the IMAT options. The full announcement is available via the NIH grants guide link, and NIH’s Office of Extramural Research webmaster contact is provided for access or technical issues.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Application and Use of Transformative Emerging Technologies in Cancer Research (R21)

Previous opportunity: Innovative and Applied Emerging Technologies in Biospecimen Science (R21)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA CA 09 005

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA CA 09 005) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 09 005", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.